


## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1. (Currently Amended) A tetrahydroquinoline derivative according to Formula 1,



Formula I

or a pharmaceutically acceptable salt thereof, wherein

R<sup>1</sup> and R<sup>2</sup> are H or R<sup>1</sup> and R<sup>2</sup> are Me H, Me;

R<sup>3</sup> is (2-6C)heterocycloalkyl(1-4C)alkyl, (2-5C)heteroaryl(1-4C)alkyl, (6C)aryl(1-4C)alkyl, (1-4C)(di)alkylaminocarbonylamino(2-4C)alkyl, (2-

6C)heterocycloalkylcarbonylamino(2-4C)alkyl, R<sup>5</sup>-(2-4C)alkyl or R<sup>5</sup>-carbonyl(1-4C)alkyl;

R<sup>4</sup> is (2-5C)heteroaryl, (6C)aryl, (3-8C)cycloalkyl, (2-6C)heterocycloalkyl or (1-6C)alkyl

R<sup>5</sup> is (di)(1-4C)alkylamino, (1-4C)alkoxy, amino, hydroxy, (6C)arylamino, (di)(3-4C)alkenylamino, (2-5C)heteroaryl(1-4C)alkylamino, (6C)aryl(1-4C)alkylamino, (di)[(1-4C)alkoxy(2-4C)alkyl]amino, (di)[(1-4C)alkylamino(2-4C)alkyl]amino, (di)[amino(2-4C)alkyl]amino or (di)[hydroxy(2-4C)alkyl]amino.

2. (Original) The derivative according to claim 1 wherein R<sup>3</sup> is (2-6C)heterocycloalkyl(1-4C)alkyl, (2-5C)heteroaryl(1-4C)alkyl, (2-6C)heterocycloalkylcarbonylamino(2-4C)alkyl, R<sup>5</sup>-(2-4C)alkyl or R<sup>5</sup>-carbonyl(1-4C)alkyl.
3. (Previously Presented) The derivative according to claim 2 wherein R<sup>5</sup> is (di)(1-4C)alkylamino, amino, (di)(3-4C)alkenylamino, (2-5C)heteroaryl(1-4C)alkylamino or (6C)aryl(1-4C)alkylamino.
4. (Previously Presented) The derivative according to claim 3 wherein R<sup>5</sup> is (di)(1-4C)alkylamino or amino.
5. (Previously Presented) The derivative according to claim 4 wherein R<sup>5</sup> is (di)(1-4C)alkylamino.
6. (Previously Presented) The derivative according to claim 1 wherein R<sup>4</sup> is (6C)aryl.
7. (Previously Presented) The derivative according to claim 6 wherein R<sup>3</sup> is (2-6C)heterocycloalkyl(1-4C)alkyl, (2-5C)heteroaryl(1-4C)alkyl or R<sup>5</sup>-(2-4C)alkyl.
8. (Previously Presented) A pharmaceutical composition comprising the tetrahydroquinoline derivative of claim 1 and at least one pharmaceutically suitable auxiliary.

9-10 (Canceled).

11. (Currently Amended) A method of fertility regulation comprising administering an FSH receptor activity modulating amount of the pharmaceutical composition of claim 8 to a patient in need thereof.